Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.
View Top Employees from Annexon Biosciences| Website | http://www.annexonbio.com |
| Ticker | ANNX |
| Revenue | $20.6 million |
| Funding | $633.8 million |
| Employees | 88 (88 on RocketReach) |
| Founded | 2011 |
| Address | 180 Kimball Way Suite 200, South San Francisco, California 94080, US |
| Phone | (650) 822-5500 |
| Fax | (650) 636-9773 |
| Technologies |
JavaScript,
HTML,
PHP
+41 more
(view full list)
|
| Industry | Biotechnology, Biotechnology Research, Drug Manufacturing & Research, Drug Discovery, Pharmaceuticals, Science and Engineering, Healthcare, Health Care, Health Diagnostics, Life Science, Therapeutics |
| Web Rank | 5 Million |
| Keywords | Annexon Biosciences, Annexon, Annexonbio, Leslie Annexon Biosciences, Neurodegeneration "Public Policy" Director |
| Competitors | Axsome Therapeutics, Inc., Checkmate Pharmaceuticals, Galera Therapeutics, Inc., GlycoMimetics, Leap Therapeutics |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 80 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 541711 Companies, NAICS Code 54 Companies, NAICS Code 32 Companies, NAICS Code 5417 Companies |
Looking for a particular Annexon Biosciences employee's phone or email?
Annexon Biosciences Questions
The Annexon Biosciences annual revenue was $20.6 million in 2024.
Jamie Dananberg is the Chief Medical Officer of Annexon Biosciences.
88 people are employed at Annexon Biosciences.
Annexon Biosciences is based in South San Francisco, California.
The NAICS codes for Annexon Biosciences are [325, 541, 54171, 541711, 54, 32, 5417].
The SIC codes for Annexon Biosciences are [28, 283, 80].
Top Annexon Biosciences Employees
-
View
Lori Taylor
Senior Vice President, Portfolio Strategy and Operations at Annexon Biosciences
South San Francisco, CA, US25 -
4
-
5+5
-
52
-
ViewHenk-Andre Kroon
SVP, Head of Translational Medicine at Annexon Biosciences
San Francisco, CA, US25 -
1
-
45+
-
ViewLarry Mattheakis
EVP and Chief Scientific Officer at Annexon Biosciences
California, United States35+
Related Companies
